Figure 5.

Quantification of SLPI expression in leukocytes. (A) The percentage of SLPI-immunoreactive leukocytes isolated from the tail vein prior to injury (pre-Injury) and at 1, 3 and 11 h after intraperitoneal injection of recombinant mouse SLPI or vehicle (n = 3). There is an increase in SLPI⁺ leukocytes after injury in recombinant SLPI- and vehicle-treated mice (all times significantly increased relative to pre-Injury; P < 0.05). However, the percentage of SLPI⁺ leukocytes is significantly higher in recombinant SLPI-treated mice, relative to vehicle-treated controls at all time-points. (B) Quantification of the intensity of SLPI immunofluorescence measured by confocal microscopy in over 150 cells per group per time-point shows that SLPI intensity is significantly higher in recombinant SLPI-treated mice as compared to vehicle-treated controls at all time-points examined (P < 0.05). There is a 96% increase in SLPI intensity as early as 1 h after recombinant SLPI-treatment. This intensity increases to about 3.2-fold of control at 11 h after treatment. *P < 0.05 versus pre-injury and **P < 0.05 at specific time-points; >150 cells analysed in each of three mice per group (n = 3 per group).